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www.sciencedirect.comEditorialditor-in-ChiefInfectious disease remains an important threat to mankind.
Pathogens can cause severe illness, deformation, disability, or
death, and might be responsible for certain kinds of cancer,
neurological diseases and heart diseases, etc. Anti-bacterial drugs
have been considered amongst the most paramount achievements
of the 20th century in medicine, and indeed application of
antibiotics have made signiﬁcant contribution to human health
and medical practice. In the past decade, the success in treating
pathogen infection has been extended from bacterial infection to
viral diseases. Recent clinical results of new drugs against AIDS
and hepatitis C have been very encouraging.
However, the success in drug R&D against infectious diseases
has been accompanied with the emergence of drug-resistant strains
as well as newly emerging infectious pathogens. It represents an
endless war between humans and pathological microbes, and is
considered a grand challenge in global health. To meet the need,
biologists in the ﬁeld of drug discovery for infectious diseases16/j.apsb.2014.07.002
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an open access article under the CC BY-NC-ND licenseshow more interest on acquiring new targets on pathogens; some
of them start their research on innate immunity as well as host
molecules required for pathogen replication. New compounds with
novel backbone structures and anti-pathogenic activity are subjects
of interest for medicinal chemists. The goal is to discover drugs
that act via new mechanisms against pathogens, especially drug-
resistant pathogens and newly emerging infectious agents. This
special issue collects reviews and research articles from groups
that have a long history of doing research on drugs against
infectious diseases. I hope the forum to be informative for our
readers.ECover storyu-Tao-GuoChronic hepatitis B virus (HBV) infection affects more than 350
million people worldwide and remains to be one of the most
important public health challenges. While currently available
antiviral therapies can efﬁciently reduce HBV load as well as
prevent liver disease progression, cure or durable off-drug control
of HBV infection are rarely achieved. Encouraged by the recent
milestone of therapeutic cure of chronic hepatitis C virus infection,
signiﬁcant academic and industrial efforts are now focusing onﬁnding a cure for chronic hepatitis B. The review article by Chang
and colleagues thoroughly analyzes the major obstacles for the
functional cure of chronic HBV infection. Therapeutic strategies to
overcome these obstacles are proposed.Jademy of Medical Sciences and Chinese Pharmaceutical Association.
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